About Us

A Clear Focus on Eye Disorders

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders.

Targeting Front and Back of the Eye Indications

Our pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications.

Nyxol® Eye Drops

Our lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size and improve visual acuity. Nyxol is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia.

Nyxol is an investigational 505(b)(2) product candidate that has been studied in over 230 subjects across 7 completed Phase 1 and 2 trials.

See Nyxol Clearer

APX3330

Our second product candidate, APX3330, is a twice-a-day oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema.

APX3330 has been studied  in over 440 patients across six Phase 1 and five Phase 2 trials.

See APX3330 Clearer

Clinical Trials with a Broad Range of View

We plan to initiate two Phase 3 registration trials and two Phase 2 trials across four ophthalmic indications in the fourth quarter of 2020 through the first quarter 2021.

View Our Trials

Aligning Our Vision with Partners

As part of our strategy, we continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation and commercialization of drugs in key global markets.

Partnership Opportunities

Leadership in Drug Development

Our leadership team is comprised of seasoned professionals with decades of experience in the pharmaceutical, biotech and medical research industries. Meet our teams.